NEW YORK, January 23, 2017 /PRNewswire/ --
Stock-Callers.com today presents the following Generic Drugs equities for assessment: Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), Sophiris Bio Inc. (NASDAQ: SPHS), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and Agile Therapeutics Inc. (NASDAQ: AGRX). These companies are part of the Healthcare sector which turned somewhat lower in late trade on Friday, January 20th, 2017, with the NYSE Health Care Index dropping about 0.3%, while shares of health care companies in the S&P 500 also were sinking by 0.3% as a group. Register now and get full and free access to our downloadable research reports on these stocks at:
Last Friday, shares in Coral Gables, Florida-based Catalyst Pharmaceuticals Inc. ended the session 0.83% lower at $1.19. The stock recorded a trading volume of 348,657 shares. The Company's shares have advanced 2.59% in the last one month and 13.33% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 5.34% and 24.13%, respectively. Furthermore, shares of Catalyst Pharma, which focuses on the development and commercialization of therapies for people with rare debilitating diseases, have a Relative Strength Index (RSI) of 53.96.
On December 15th, 2016, Catalyst Pharmaceuticals announced that the first patient has been enrolled into its second Phase-3 clinical trial (designated as LMS-003) to evaluate the efficacy and safety of Firdapse® (amifampridine phosphate) in patients with Lambert-Eaton myasthenic syndrome. In October 2016, Catalyst announced that it had reached an agreement with the US Food and Drug Administration (FDA) under a Special Protocol Assessment for the protocol design, clinical endpoints, and statistical analysis approach in this additional Phase-3 trial. Access our complete research report on CPRX for free at:
La Jolla, California-based Sophiris Bio Inc.'s stock finished 2.82% higher at $2.92 with a total trading volume of 445,375 shares. The Company's shares have gained 0.69% in the last one month and 4.29% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 3.70% and 8.69%, respectively. Moreover, shares of Sophiris Bio, which focuses on the development of products for the treatment of urological diseases, have an RSI of 52.07. The complimentary research report on SPHS can be downloaded at:
Shares in Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc. closed the day 2.71% lower at $14.35. The stock recorded a trading volume of 253,173 shares. The Company's shares have gained 22.75% over the previous three months. The stock is trading above its 200-day moving average by 19.39%. Moreover, shares of Momenta Pharma, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases, have an RSI of 42.43.
On January 05th, 2017, Momenta Pharma and CSL Limited announced that they have entered into an exclusive research collaboration and worldwide license agreement to develop and commercialize Fc multimer proteins, including Momenta's M230, a selective immunomodulator of Fc receptors, which is expected to enter the clinic in 2017. Momenta will receive a $50 million upfront license fee from CSL and is eligible to receive future milestone and royalty payments for M230. In addition to advancing M230, CSL and Momenta intend to enter into a research collaboration to develop additional Fc multimer proteins that may originate from Momenta's or CSL's research. Register for free on Stock-Callers.com and get access to the latest PDF format report on MNTA at:
Princeton, New Jersey headquartered Agile Therapeutics Inc.'s shares recorded a trading volume of 180,820 shares last Friday, and closed 2.11% lower at $2.32. The stock is trading 60.23% below its 50-day moving average. Shares of the Company, which focuses on the development and commercialization of prescription contraceptive products for women, have an RSI of 12.07.
On January 03rd, 2017, Agile Therapeutics announced positive top-line results from its Phase-3 SECURE clinical trial of Twirla®, its investigational low-dose combined hormonal contraceptive patch. SECURE was a multicenter, single-arm, open-label, 13-cycle trial that evaluated the safety, efficacy and tolerability of Twirla in 2032 healthy women, aged 18 and over, at 102 experienced investigative sites across the US. The Company plans to resubmit its new drug application for Twirla in H1 2017 on the basis of the SECURE results and other information relating to the manufacture of Twirla. SECURE was conducted to address issues raised by the US FDA in its 2013 Complete Response Letter to the Company. Download your free research report on AGRX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA